Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis [0.03%]
基于抗CD38的四联方案在不适合移植的新诊断多发性骨髓瘤患者中的生存影响：网状meta分析和个体患者数据Meta分析
João Tadeu Damian Souto Filho,Lucas Oliveira Cantadori,Edvan de Queiroz Crusoe et al.
João Tadeu Damian Souto Filho et al.
Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and isatuximab have demo...
Meta-Analysis
Blood cancer journal. 2025 Dec 6;15(1):212. DOI:10.1038/s41408-025-01413-7 2025
Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database [0.03%]
美国医疗理赔数据库中弥漫性大B细胞淋巴瘤患者的真实世界治疗模式和临床结局
Mazyar Shadman,Jennifer S Harper,Alex Bokun et al.
Mazyar Shadman et al.
Treatment options for diffuse large B-cell lymphoma (DLBCL) have expanded, but real-world data on treatment patterns and outcomes remain limited. This study examined real-world outcomes in DLBCL patients treated between 10/1/2015 and 6/30/2...
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia [0.03%]
订正：CPX-351在小于60岁继发性急性髓系白血病患者中的真实世界多中心疗效分析
Calogero Vetro,Bruno Garibaldi,Francesco Grimaldi et al.
Calogero Vetro et al.
Published Erratum
Blood cancer journal. 2025 Dec 4;15(1):213. DOI:10.1038/s41408-025-01431-5 2025
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma [0.03%]
伊沙佐米新诊断的多发性骨髓瘤患者的最终OS分析：TOURMALINE-MM3和-TM4随机对照试验结果
Meletios A Dimopoulos,Sagar Lonial,Wee-Joo Chng et al.
Meletios A Dimopoulos et al.
TOURMALINE-MM3 (NCT02181413) and -MM4 (NCT02312258) were phase 3 studies of fixed-duration, single-agent ixazomib maintenance in post-transplant (TOURMALINE-MM3)/transplant-ineligible (TOURMALINE-MM4) patients with newly diagnosed multiple ...
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy [0.03%]
布鲁顿酪氨酸激酶抑制剂治疗停药的瓦尔登斯特伦巨球蛋白血症患者的长期结局和治疗模式
Karan L Chohan,Lorenzo Gensini,Sherif Seif et al.
Karan L Chohan et al.
Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study [0.03%]
自身免疫性疾病中多重用药的淋巴瘤风险：来自LIFE研究的分析
Ami Inokuchi,Haryoon Kim,Masatoshi Sakurai et al.
Ami Inokuchi et al.
Autoimmune diseases (AIDs) are associated with an increased risk of lymphoma. Although treatment strategies have changed substantially in AIDs, recent evidence regarding this association is lacking. Particularly, the impact of novel immunos...
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience [0.03%]
关于替塞利单抗治疗多发性骨髓瘤的疗效在外周浆细胞瘤患者中的影响：美国骨髓瘤免疫治疗联盟真实世界经验
Aimaz Afrough,Danai Dima,Beatrice Razzo et al.
Aimaz Afrough et al.
Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patient...
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies [0.03%]
真实世界证据在多发性骨髓瘤治疗监管批准中的应用
Lockwood Taylor,Angela Chen,Amy Pierre
Lockwood Taylor
CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas [0.03%]
CDK9是GATA-3驱动的和MCL-1独立的T细胞淋巴瘤的依赖因素
Chenguang Wang,Suhaib Abdelrahman,Xiangrong Geng et al.
Chenguang Wang et al.
The transcription factor GATA-binding protein 3 (GATA-3) regulates oncogenic transcriptional programs across diverse T-cell lymphomas, including subsets of both peripheral and primary cutaneous T-cell lymphomas. These GATA-3 dependent trans...
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4 [0.03%]
CARTITUDE-1、CARTITUDE-2和CARTITUDE-4研究中接受西妥昔单抗自体T细胞治疗的复发/难治多发性骨髓瘤患者的颅神经麻痹临床经验
Paula Rodríguez-Otero,Surbhi Sidana,Mathilde Kouwenhoven et al.
Paula Rodríguez-Otero et al.